

CURRICULUM VITAE
ALISTAIR I. FYFE M.D., Ph.D. FACC FRCP(C).

EDUCATION:

1978-81 University of Tasmania, B. Med.Sc.(Hons) (Immunology)
1982-84 University of Tasmania, M.B.B.S. (Medicine)
1992-95 University of California, Los Angeles, Ph.D. (Molecular Biology)

POSTDOCTORAL TRAINING:

1985-86 Internship, Royal Hobart Hospital, University of Tasmania, Hobart, Australia.
1986-89 Resident, Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
1989-90 Clinical Fellow and Chief Resident, Cardiology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
1990-91 Clinical Fellow and Chief Resident, Cardiology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
1991-94 Research Fellow, Cardiology, UCLA Medical Center, UCLA, Los Angeles, CA
1994-95 Specialist Training & Advanced Research Fellow, Cardiology, UCLA Medical Center, UCLA, Los Angeles, CA

ACADEMIC APPOINTMENTS:

1986-89 Clinical Fellow in Medicine, University of British Columbia
1989-91 Clinical Fellow in Cardiology, University of Toronto
1991-94 Research Fellow in Cardiology, University of California, Los Angeles
1994-95 STAR Fellow in Cardiology, University of California, Los Angeles
1995-99 Assistant Professor of Medicine, University of California, Los Angeles
1995-96 Director, Fellowship Training Program in Cardiology, UCLA
1995-98 Director, Center for Cholesterol and Lipid Management, UCLA
1996-98 Associate Member, UCLA Molecular Biology Institute

CLINICAL/HOSPITAL APPOINTMENTS:

1986-89 Resident Physician, University British Columbia, Vancouver General Hospital
1989-91 Clinical Fellow, University of Toronto, The Toronto Hospital, ON
1991-95 Fellow in Cardiology, UCLA Medical Center, Los Angeles, CA
1995-99 Attending Cardiologist, UCLA Medical Center, Los Angeles, CA
1999-00 Cardiologist, HeartPlace, Medical City Dallas Hospital, Dallas, TX
1999-02 Cardiologist, Presbyterian Hospital of Plano, Plano, TX
1999-03 Cardiologist, Las Colinas Hospital, Las Colinas, TX
1999-03 Cardiologist, North East Medical Center, Bonham, TX
1999-04 Cardiologist, The Dallas Heart Group, Medical City Dallas Hospital, Dallas, TX
2003-05 Chief, Cardiology, Medical City Dallas Hospital
2004- Director, Primary and Secondary Cardiac Prevention, Medical City Hospital, Dallas, TX
2004- Cardiologist, Cardiac Associates of Dallas, Medical City Hospital, Dallas, TX

SCIENTIFIC ACTIVITIES:**Editorial Boards**

1993-1998 Reviewer, Atherosclerosis Thrombosis and Vascular Biology
 1993-1998 Reviewer, American Journal of Pathology
 1994-1999 Reviewer, Circulation
 1994-1998 Reviewer, Journal of Clinical Investigation
 1995-1998 Reviewer, Journal of Lipid Research
 1995-1998 Reviewer, Journal of Heart and Lung Transplantation
 1995-1998 Reviewer, Diabetes

CERTIFICATION AND LICENSURE:

Medical License: Tasmania, Australia,
 British Columbia, Canada,
 Ontario, Canada,
 State of California, Texas

Board Certification: Diplomate, American Board of Internal Medicine, #129285
 Fellow, Royal College of Physicians of Canada in Internal Medicine, #388485
 Diplomate, American Board of Internal Medicine, Cardiovascular Disease,
 #129285; RECERTIFIED 10/2002

Other Certification: Fellow, Royal College of Physicians of Canada in Cardiology , #388485
 United Network for Organ Sharing (UNOS) Certified Transplant Cardiologist
 Heart Rhythm Society Certificate of Special Competence in Cardiac Pacing and
 Defibrillation 2005.

HONORS AND AWARDS:

1982 The Royal Australian College of Ophthalmology Prize, University of Tasmania
 1983 The Kathleen Menzies Travelling Scholarship, University of Tasmania
 1984 The Frank Fay Prize in Surgery, University of Tasmania
 1984 The John Daly Prize in Oncology, University of Tasmania
 1987 The Knoll Clinical Research Prize in Medicine, University of British Columbia
 1990 The Ursula Bangs Research Prize in Cardiology, University of Toronto
 1991 The Ursula Bangs Research Prize in Cardiology, University of Toronto
 1991 The Department of Medicine Research Prize, The Toronto Hospital
 1991 The Department of Medicine Research Prize, University of Toronto
 1991 The Syntex Bronze Heart Award in Cardiology, University of Toronto
 1991 Heart & Stroke Foundation of Canada, Fellowship
 1991 Medical Research Council of Canada, Fellowship
 1992 Medical Research Council of Canada, Clinician-Scientist Award
 1993 Clinical Science Prize, Los Angeles Affiliate of American Heart Association
 1993 Young Investigator Award, American Heart Association
 1993 The Student Presentation Award, Canadian Cardiovascular Society
 1994 Specialist Training in Academic Research Award, UCLA Department of
 Medicine.
 1994 Young Investigator, International Atherosclerosis Society
 1995 Irvine H. Page Arteriosclerosis Research Young Investigator, American Heart
 Association.
 1996 Marquis Who'sWho in Science and Engineering
 1997 Marquis Who'sWho in America
 1997 Marquis Who'sWho in The West
 1997 Marquis Who'sWho in The World
 1998 Marquis Who'sWho in Medicine and Healthcare.
 1999 Top 2000 Scientists of the 20th Century
 2005 Marquis Who'sWho in American Education

MEMBERSHIP AND OFFICES IN PROFESSIONAL SOCIETIES:

1990 Royal College of Physicians of Canada - Fellow
1991 International Society for Heart Transplantation - Member
1993 American Association for the Advancement of Science - Member
1994 American Heart Association,, Arteriosclerosis Council - Fellow
1995 American College of Cardiology - Fellow
1995 American Federation of Clinical Research - Member
1996 American Diabetes Association - Member
1996-99 Lipid Management in Clinical Practice - National Faculty
1996 Vascular Biology Working Group - National Faculty
1998 Western Lipid Association - Founding Member

COMMITTEE AND ADMINISTRATIVE SERVICES:

National

1995-1997 Member, Cardiac Sub-committee, Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection, NHLBI

University of California, Los Angeles

1995-1996 Director, Cardiology Fellowship Program, Department of Medicine, UCLA
1995-1998 Member, STAR Committee, Department of Medicine, UCLA
1995-1998 Member, Medical Student Training Program, UCLA
1996-1998 Member, Molecular Biology Institute PhD Committee, UCLA

Medical Director / External Consultant / Speakers Bureau

1994-98 Merck Human Health Division
1995- Parke-Davis/Warner Lambert/Pfizer
1996-99 Value Health Sciences/Protocare Sciences, Santa Monica CA
1999 Cardiovascular Provider Resources, Dallas, TX
1999 Worldwide Health Management Clinics Inc.
1999 - 01 Bayer Pharmaceuticals
2000 LipoSciences
2000- Glaxo-Smith-Kline Pharmaceuticals
2001- Kos Pharmaceuticals
2000 - Abbott Laboratories
1999- Astra Zeneca Pharmaceuticals
2002 Wyeth Ayerst Pharmaceuticals
2001-3 Member, Texas Medical Association, HeartCare Partnership
2001-3 Member, Texas Medical Association, Council on Scientific Affairs
2001-2 Medical Director, Vital-Imaging of Dallas, Plano, TX
2002- Forest Pharmaceuticals
2002- Novartis Pharmaceuticals

REPRESENTATIVE INVITED LECTURES:

May 1991	"Coronary Sinus Cytokines after Cardiac Transplantation" American Society of Transplant Physicians, Chicago, IL
October 1992	"Merck Health Science Services, Lipid Young Investigators", Rahway NJ
October 1992	"Diagnosis and Management of Pulmonary Hypertension" Los Angeles Children's Hospital, Department of Pediatric Pulmonology, Los Angeles, CA
November 1992	"Endothelial-Monocyte Interactions after Cardiac Transplantation" Cardiology Grand Rounds, The Toronto Hospital, University of Toronto, Toronto, Canada
February 1993	"Use of ACE Inhibitors in Advanced Heart Failure" UCLA Heart Failure, Heart and Lung Transplant Symposium, Marina del Ray, CA
February 1993	"Transplant Atherosclerosis" Cardiovascular Issues in the 90's, University of Toronto, Orlando, FL
August 1993	"Pathogenesis of Atherosclerosis" 5th International Symposium on Cardiovascular Pharmacotherapy, Minneapolis, MN
September 1993	"Interaction of Human Mononuclear Cells with Porcine Endothelium" 2nd International Congress on Xenotransplantation, Cambridge, England
October 1993	Molecular Cellular Biology of the Vessel Wall, American Heart Association, Boston, MA
May 1994	Course Director "Plaque Stabilization: The New Biology", Cholesterol Consensus Conference, Newport Beach, CA,
June 1994	Graft Endothelial-Smooth muscle cell Cocultures as a Model for Post Transplant Vascular Interactions. 5 th Annual Alexis Carrel Conference, Munich, Germany
June 1994	Psoralen/UV Therapy Prevents Mononuclear cell-Endothelial Interactions in-vitro. 5 th Annual Alexis Carrel Conference, Munich, Germany
January 1995	"Genetic Modification of Monocyte-Endothelial Responses in Relation to Transplant Atherosclerosis" Harvard School of Public Health, Boston, MA
January 1995	"Biologic Modification of Allograft Endothelium Using Recombinant Adenovirus Mediated Gene Transfer. Second Symposium on Cardiac Allograft Vasculopathy. St Louis, MO
February 1995	"Xenografts: Will it be Possible" UCLA Lung Transplant Symposium, Laguna Niguel, CA
March 1995	"Maximizing Endothelial Responses to Minimally Oxidized LDL" Lipoprotein Oxidation Conference, University of Washington, Seattle, WA
March 1995	"Gene Therapy in Cardiac Transplantation", Molecular Approaches to Vascular Repair Symposium, American College of Cardiology Annual Scientific Sessions, New Orleans, LA
September 1995	"Role of Lipids in Diabetic Macrovascular Complications" UCLA Endocrinology Grand Rounds, Los Angeles, CA.
October 1995	"Atherosclerosis Regression and Lipid Lowering" Harbor-UCLA Cardiology Grand Rounds, Torrance CA.
November 1995	"Gene Transfer in Heart Transplantation" International Symposium on Heart Failure and Heart Transplantation. Anaheim CA.
December 1995	"Diagnosis and Management of Hypercholesterolemia" Internal Medicine Grand Rounds, University of California, Irvine, CA
December 1995	Course Director and "Plaque Stabilization: The New Biology" Lipid Lowering Therapy: Insights for the 21st Century, UCLA Continuing Medical Education, Santa Monica, CA
December 1995	"Genetic Insights into Acute and Chronic Cardiac Transplant Rejection" Cardiology Grand Rounds, University of Wisconsin, Milwaukee, WI.
February 1996	"SAA as an Apolipoprotein: Implications in Atherosclerosis II" Gordon Conference on Serum Amyloid A, Ventura CA
May 1996	"Primary Prevention of Coronary Artery Disease: Antioxidants, Lipids, Aspirin and More" 23rd Annual UCLA Family Practice Refresher Course, Santa Monica, CA
June 1996	Course Director, Lipid Lowering Therapy, and "Non-pharmacologic Interventions, Anti-oxidants, Gene Therapy" Insights for the 21st Century, UCLA Continuing Medical Education, Santa Barbara, CA

July 1996 "Lipoproteins and Atherogenesis in NIDDM", Non-Insulin-Dependent Diabetes Mellitus: Research Developments as Applied to Therapy. UCLA Continuing Medical Education. Santa Monica, CA

August 1996 "Current and Future Concepts in Lipid Management", UCLA Internal Medicine Grand Rounds. Los Angeles CA.

September 1996 "The Cholesterol Controversy" KCET Los Angeles, documentary.

September 1996 "Gene Therapy, Current Applications, Future Implications, Historical and Scientific Background" St John's Hospital and Health Center, Santa Monica CA.

October 1996 "Diabetes and AGEing: Pathogenesis of Diabetic Macrovascular Disease". Olive View Veterans Hospital, Cardiology Grand Rounds. Van Nuys, CA

October 1996 "Antioxidant Therapy and Cardiovascular Disease", Loma Linda University Primary Care Update, Loma Linda, CA.

October 1996 "Gene Therapy in Cardiac Transplantation" Los Angeles Gene Therapy Affinity Group, USC Children's Hospital, Los Angeles, CA

November 1996 Chairman "Transgenic Models of Atherosclerosis" American Heart Association, Annual Scientific Sessions, New Orleans, LA

December 1996 "Current Controversies in the use of Statins in Cholesterol Lowering", Merck Human Health Advanced training, San Francisco CA

January 1997 "Anti-atherogenic effects of HMG-CoA Reductase Inhibitors" Parke-Davis West CBU Speakers Bureau Training Meeting, Phoenix, AZ

February 1997 "AGEing of Lipoproteins and Atherogenesis in Diabetes" Endocrinology Grand Rounds, University of Southern California, Los Angeles, CA.

February 1997 "Lipid Management Update" Cardiology Grand Rounds, Harbor-UCLA Medical Center, Los Angeles, CA.

February 1997 "Advanced Glycosylation and its Role in Diabetic Macrovascular Disease" Medical Grand Rounds, St Josephs Medical Center, Burbank CA.

March 1997 "Recent Advances in Lipid Management" Medical Grand Rounds, Porterville CA.

March 1997 "Molecular Basis of Endothelial Dysfunction" Vascular Biology Working Group, Anaheim, CA.

March 1997 "Assessment and Management of Cardiovascular Risk" Medical Grand Rounds, Kaiser Permanente, Baldwin Park CA.

April 1997 "Diabetic Dyslipidemia" Merck Managed Care Consultants Meeting, Pasadena CA.

April 1997 "Recent Advances in the Management and Prevention of Stroke" Medical Grand Rounds, Little Company of Mary Hospital, Torrance CA.

April 1997 "Management of Diabetic Dyslipidemia" Merck Human Health Speakers Bureau Training Meeting, San Diego CA.

April 1997 "Current Concepts in Lipid Management" California Association of Nurse Practitioners, Anaheim CA.

May 1997 "Role of Lipid Lowering after Cardiac Transplantation" Northwest Transplant Society, Spokane WA.

June 1997 "New Approaches to the Management of Hypercholesterolemia" Pharmacy Grand Rounds, Kaiser Permanente, Los Angeles, CA

June 1997 "Diabetic Dyslipidemia and Macrovascular Complications" Endocrinology Grand Rounds, UCLA Medical Center, Los Angeles, CA.

July 1997 "AGEing and its Role in Diabetic Vascular Disease" Medical Grand Rounds, University of California, Irvine, CA.

September 1997 "Lipid Management in Diabetes Mellitus" Medical Grand Rounds, Daniel Freeman Hospital, Inglewood, CA.

September 1997 "Heart Disease in Women" Medical Grand Rounds, St Joseph's Hospital, Vancouver WA

September 1997 "Role of Lipid Lowering Therapy after Cardiac Transplantation" University of Oregon Transplant Society, Portland OR.

September 1997 "Pathogenesis of Vascular Complications in Diabetes Mellitus" Endocrinology Grand Rounds, Wadsworth Veterans Hospital, Los Angeles, CA.

September 1997 "Lipid Lowering: Its Evolving Role in the Prevention and Treatment of Coronary Artery Disease". Menopause Management 1997: In Search of a Consensus. UCLA Continuing Medical Education, Anaheim CA.

October 1997 "NCEP Guidelines for Cholesterol Management" Parke-Davis South Central CBU Speakers Bureau Training Meeting, Phoenix AZ.

November 1997 "Atherosclerosis: Inflammation and Immunity" Cardiology Grand Rounds, Sepulveda Veterans Hospital, Los Angeles, CA.

November 1997 "Diabetes and Cardiovascular Disease" American Heart Association 70th Scientific Sessions Live Worldwide Interactive Satellite Broadcast.

December 1997 "Advances in Diagnosis and Management of Cardiovascular Risk". Medical Grand Rounds, Columbia West Hills Medical Center, Los Angeles, CA.

January 1998 "Management of Cardiovascular Risk" UCLA Family Practice Grand Rounds.

February 1998 "How to Organize and Manage a Lipid Clinic" St Vincents Hospital, Topeka, Kansas.

February 1998 "Managing Lipids from a Cardiologists Perspective" " Parke-Davis North Central CBU Speakers Bureau Meeting, Dallas, TX.

March 1998 "Comparative Efficacy of HMG-CoA Reductase Inhibitors" Parke-Davis West CBU Speakers Bureau Training meeting, Atlanta GA.

March 1998 "Mechanisms for Age-Dependent Decline in Endothelial Function" The Living Lining, The Endothelium as a Target for Therapy for Cardiovascular Disease. University of Florida CME Program, Atlanta GA

March 1998 "Atherosclerosis as an Immune Disease", Visiting Professor, Scripps Research Institute, San Diego CA

March 1998 "Rationale and Practical Application of Guidelines for Cholesterol Lowering" Rush-Presbyterian-St Lukes Hospitals CME Program. San Diego CA.

April 1998 "Managing Lipids from a Cardiologists Perspective" Oakwood Hospital Fifth Annual Cardiology Update, Detroit MI.

April-May 1998 "The High Risk Patient without CHD" Lipid Management in Clinical Practice National Teleconferences.

April 1998 "Comparative Efficacy of Statins in Cholesterol Lowering" Parke-Davis South Eastern CBU Speakers Bureau Training Meeting, Montreal, Canada.

April 1998 "Management of Lipids from a Cardiologists Perspective" Parke-Davis North Central CBU Speakers Bureau Meeting, Sarasota,, FL

April 1998 "Recent Advances in Lipid Management" Parke-Davis West CBU, Advanced Training Seminar, San Francisco CA.

May 1998 Cardiovascular Risk Reduction: Clinical Implications of Newer Therapies" University of California, San Francisco at Fresno CA.

May 1998 Assessment and Management of Cardiovascular Risk" Kern Medical Center, CME Program, Bakersfield, CA.

May 1998 "Lipid Management Update" Medicine Grand Rounds, St Vincents Hospital, Santa Fe NM.

May 1998 "Management of Cardiovascular Risk" Grand Rounds Kirtland Air Force Base Medical Center, Albuquerque, NM

June 1998 "Lipid Management from the Cardiologist's Perspective" Parke-Davis North Central CBU Speakers Bureau Meeting, Chicago IL.

July-August 1998 "Management of Hyperlipidemia" National Teleconference series, TeleSessions, NY

October 1998 "Cost Effective Management of Cardiovascular Risk" Lovelace Medical Center Grand Rounds, Albuquerque NM

October 1998 "Aggressive Lipid Lowering" San Juan Medical Center Grand Rounds, Farmington, NM.

December 1999 "Managing Global Cardiovascular Risk", Baylor University, Dallas, TX

September 2000 "Women have Broken Hearts Too: Cardiovascular Disease after Menopause" Texas Academy of Family Physicians, Houston TX.

March 2001 "Advisors on Cholesterol: Helping to Initiate and Explore Venues for Education" National Cholesterol Consultants Meeting, Puerto Rico.

March 2001 "Management of Cholesterol after Cardiac Transplantation" International Society of Transplant Nurses, Dallas, TX

October 2001 New Modalities to Measure and Modify Cardiovascular Risk. University of North Texas Family Practice Update, Padre Island, TX

September 2002 Site Specific Lipoprotein Sampling: Insights into Reverse Cholesterol Transport

and Atherogenesis. Endocrinology Grand Rounds UT Southwestern Medical Center. Dallas, TX

October 02-03 HeartCare Partnership; TMA Quality Care Initiative. Austin, Beaumont, Corpus Christi and McAllen, TX.

May 2003 Tips and Tricks in Biventricular Pacing. Biotronik Regional Consultants Meeting, Jacksonville, FL

May – Sep 03 Prevention of the Progression to Heart Failure, Medical World Conferences, Kansas City, KA, Wichita KS, Tulsa OK, Daytona Beach FL, McAllen TX, Milwaukee WI, Houston TX, Dallas TX, New Orleans LA, Anchorage AK, Pensacola FL

October 2003 Closed Loop Stimulation Algorithm for Cardiac Pacing, Detroit MI

May 2004 The Metabolic Syndrome Symposium: Organizer, Overview and Lipid Management, Texas Association of Family Physicians, Dallas, TX

May 2004 New Insights and Management of Heart Failure, Medicine Grand Rounds, Launceston General Hospital, Launceston Australia

June – Sep 04 Management of the Diabetic Hypertensive Patient. Medical World Conferences; New York NY, Portland OR, Orlando FL, Tampa FL

September 2004 Closed Loop Stimulation Pacing algorithm. Biotronik Western Regional Update, Aspen CO

September 2004 An LDL of 70mg/dl is Optimal, Texas Tech University, Family Practice Update, Amarillo TX

October 2004 Closed Loop Stimulation Algorithm in Cardiac Pacing, Biotronik World Headquarters, Berlin, Germany.

November 2004 Lipoprotein Metabolism and Aggressive Lipid Lowering, Cooper Clinic CME, Dallas TX.

April 2005 The CLS pacemaker sensor algorithm, Biotronik Regional Update, Phoenix, AZ

April 2005 "Mechanisms and Management of Statin Intolerance" Texas Academy of Family Practice, Amarillo, TX

March 2006 Management of Diabetic Dyslipidemia. College of Osteopathic Family Physicians Annual Meeting, Grapevine TX.

RESEARCH GRANTS:

COMPLETED:

1. Endothelial mediated events in transplant atherosclerosis, Heart and Stroke Foundation of Canada 7/91 - 6/93
2. Endothelial mediated events in transplant atherosclerosis, Medical Research Council of Canada, 7/91 - 6/93
3. Role of vascular endothelium in immunity and transplant atherosclerosis. Medical Research Council of Canada 7/92 - 6/2004
4. Immune responses in atherosclerosis, Laubisch Award, University of California, 7/1/95-6/30/96.
5. Interleukin-10 in inflammatory arthritis, NIH AR-36834-09, 9/1/95-8/31/97.
6. Interleukin 10 and Mononuclear endothelial interactions, UCLA Academic Senate, 1/1/96-6/30/96
7. Role of LDL glycation and/or oxidation in diabetic macrovascular disease, Laubisch Award, University of California, 7/1/96-6/30/97.
8. A 54 week study of the safety and efficacy of atorvastatin versus simvastatin in patients with mixed dyslipidemia. Parke-Davis 981-158, 3/97 - 4/98.
9. A Double Blind Study to Evaluate the Efficacy and Safety of High Dose Simvastatin in patients with Hypercholesterolemia. Merck Human Health 128-00, 2/97 -4/98.
10. Randomized trial of the addition of troglitazone in patients with type 2 diabetes mellitus taking insulin, Parke-Davis 991-084, 2/97-8/97.
11. Randomized Assessment of Myocardial Perfusion using PET Scanning: Effects of ACAT Inhibitor CI-1011 Trial (RAMPART) Phase II, Parke-Davis 1998.
12. Treat to New Target Study, Parke Davis 1998.
13. Comparison of troglitazone with AR1624 in type 2 diabetes mellitus, Novartis.
14. Clinical evaluation of Stelid II and Stelix steroid eluting cardiac pacing leads. Protocol SBXD04v6, ELA Medical, 2000-2003
15. Clinical evaluation of the Talent DDR MV+G pacemaker with autosensing. Protocol ILYR09v8ELA Medical 2001-2002
16. Advanced Lipid Testing as a marker for coronary calcification; Principal Investigator
17. Simultaneous Right Atrial and Aortic Root Lipid Profiling. Medical City Hospital Protocol 2000.069; Principal Investigator
18. The Impact of Medical Subspecialty on Patient Compliance to Treatment. IMPACT study Kos Pharmaceuticals, 2001-2. Investigator
19. A Phase III Randomized, Double Blind Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone Vs Placebo in Advanced Chronic Heart Failure Subjects. ESSENTIAL Co-investigator 2002
20. Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: REVIVE Study. Co-Investigator.
21. Home Monitoring Technology for ICD Therapy; Wireless, Automatic, Mobile Monitoring for ICD's (WAMMI) Study. Biotronik 2003 Primary Investigator
22. Protos Heart Rate Distribution Study (PHD). Biotronic 2003, Primary Investigator
23. Registry of Cardiac Resynchronization Therapy-US (RESTORE-US), Medtronic 2003; Investigator
24. NEPTUNE II study, Astra-Zeneca 2003; Investigator

BIBLIOGRAPHY:

Completed Publications in Scientific Journals:

Peer Reviewed Publications:

1. Fyfe AI, Wright JM: Chronic acetaminophen ingestion associated with (1:7)(p11:p11) translocation and immune deficiency syndrome: *Am J. Med* 1990;88:443-4.
2. Fyfe AI, Dorian P, Daly PA, Tough J: Reversible "cardiomyopathy" following accidental exogenous adrenaline overdose. *Am J Cardiol* 1991;67:318-9.
3. Fyfe AI, Huckell VF, Burr LH, Stonier PF: Leiomyosarcoma of the left atrium: Case report and review of the literature. *Can J. Cardiol* 1991;7: 193-6.
4. Fyfe AI, Daly PA, Galligan L, Pirc L, Feindel CM, Cardella CJ: Coronary sinus sampling of cytokines after cardiac transplantation: Evidence for macrophage activation and interleukin 4 production within the graft. *J Am Coll Cardiol* 1993;21: 171-176. Letter pp21: 1522-3.
5. Fyfe AI, Stevenson LW, Berliner JA, Drinkwater DC, Laks H, Fogelman AM: Antibodies to the T cell receptor initiate LFA-1/Mac-1 dependent mononuclear cell adhesion to arterial endothelium. *J Heart Lung Transplant* 1994; 13: 230-5.
6. Fyfe AI, Stevenson, LW, Harper CM, Drinkwater DC, Laks H, Fogelman AM, Berliner JA: Recipient mononuclear cell recognition and adhesion to graft endothelium after human cardiac transplantation: Lymphocyte recognition leads to monocyte adhesion. *J Clin Invest* 1994; 94:2142-2147.
7. Fyfe AI, Qiao J-H Lusic AJ: Immune deficient mice develop typical atherosclerotic plaques on an atherogenic diet. *J Clin Invest* 1994; 94:2516-2520.
8. Ardehali A, Fyfe AI, Laks H, Drinkwater DC, Qiao JH, Lusic AJ: Direct gene transfer into donor hearts at the time of harvest. *J Thor Cardiovasc Surg*, 1995;109:716-720.
9. Fyfe AI, Rosenthal AR, Gotlieb AI: Immunosuppressive agents and endothelial repair: Prednisolone delays migration and cytoskeletal rearrangement in wounded porcine aortic monolayers. *Arterioscler Thromb Vasc Biol.* 1995; 15: 1166-1171.
10. Fyfe AI, Rothenberg LS, DeBeer, FC, Cantor RM, Rotter JI, Lusic AJ: Association of serum amyloid A proteins in coronary disease: Evidence from two distinct arteriosclerotic processes. *Circulation* 1997;96:2914-2919.
11. Oslund L, Hedrick CC, Berliner JA, Fyfe AI. Interleukin-10 gene transfer inhibits endothelial-monocyte responses to oxidized lipoproteins via I- B. *ATVB* 1999;19:2847-53.

Non Peer Reviewed Journals:

1. Fyfe AI, Harper CM, Stevenson LW, Laks H. Human mononuclear cell adhesion to porcine arterial endothelium. *Transplant Proc* 1994;26: 1544-5.
2. Fyfe AI, Stevenson LW: Enhanced monocyte transendothelial migration into graft-specific vessel wall co-cultures after cardiac transplantation. *Transplant Proc* 1995; 27: 1958-9.
3. Fyfe AI, Ardehali A, Laks H, Drinkwater DC, Lusic AJ: Biologic modification of the immune response in mouse cardiac allografts using gene transfer: *J Heart Lung Transplant* 1995;14: S165-S170
4. Fyfe AI, Hyperlipidemia, Guest Editor *Catholic Healthcare West Practice Guidelines* 1998.

Reviews and Chapters in Books:

1. Fyfe AI: Transplant Atherosclerosis: The clinical syndrome, pathogenesis and possible role as a model of spontaneous atherosclerosis. *Can J Cardiol* 1992;8: 509-519.
2. Fyfe AI & Woo M: Cardiorespiratory responses to exercise of patients with dilated cardiomyopathy. in *Exercise testing and pathophysiology in children and adolescents with cardiovascular disease*, Kaplan S ed. Progress in Pediatric Cardiology, Andover Medical Publisher 1993:2(2) 65 - 71.
3. Ardehali A, Laks H, Fyfe AI. Gene Transfer in Solid Organ Transplantation. in *Transplantation and Replacement of Thoracic Organs*, Cooper DKC ed. 1995; II-
4. Fyfe A. Immunopathogenesis of Cardiovascular Complications of HIV Infection. In *Cardiology and AIDS*. Steven E. Lipshultz ed Chapman and Hall 1997:283-297

Abstracts Presented:

- 1: Fyfe AI, Lowenthal RM, and Harlow RG.: Lack of autologous cytotoxicity by T cells in B-CLL: Clinical and Experimental Pharmacology and Physiology, 9,(5) 555, 1982.
- 2: Fyfe AI, Daly PA, Galligan L, Pirc L, Feindel CM, Cardella CJ: Coronary sinus sampling of IL-2, IL-2 Receptor, and IL-6 after cardiac transplantation. Circulation 1990;82:III-2501.
- 3: Fyfe AI, Rosenthal A, Gotlieb A: Methyl Prednisolone Inhibits Healing of Endothelial Injuries in-vitro. Canadian J Cardiol 1991;7:72A.
- 4: Fyfe AI, Daly PA, Galligan L, Feindel CM, Pirc L, Cardella CJ: Coronary sinus interleukins 4 and 6, tumor necrosis factor- and neopterin indicate macrophage and T helper 2 activation in cardiac allografts. Can J Cardiol 1991;7:96A
- 5: Fyfe AI, Dawood F, Wen W-H, Lau A, Daly PA, Liu P: . Tumor necrosis factor- causes myocardial depression through prolongation of calcium recycling. Can J Cardiol 1991;7:71A
- 6: Fyfe AI, Dawood F, Wen W-H, Liu P: Verapamil attenuates the effects of tumor necrosis factor- on myocardium. J Am Coll Cardiol 1992;19:121A.
- 7: Fyfe AI, Rosenthal A, Gotlieb A: 6- -methyl prednisolone inhibits endothelial migration in response to in-vitro injury. J Am Coll Cardiol 1992;19:204A.
- 8: Fyfe AI, Stevenson LW, Berliner JA, Navab M, Demer LL, Fogelman AM: Cardiac transplant recipient mononuclear cells bind specifically to donor endothelium. Can J Cardiol 1992;8:75B.
- 9: Fyfe AI, Stevenson LW, Kobashigawa JA, Brownfield ED, Fogelman AM: ABO blood group B endothelia bind recipient mononuclear cells with increased affinity compared to ABO-A and ABO-O. Can J Cardiol 1992;8:123B.
- 10: Fyfe AI, Stevenson LW, Baldwin GC, Demer LL, Fogelman AM: Cytomegalovirus infection of human endothelium increases binding of cardiac transplant recipient mononuclear cells. Can J Cardiol 1992;8:123B.
- 11: Fyfe AI, Brownfield ED, Kobashigawa JA, Drinkwater DC, Laks H: Rh Incompatible cardiac transplantation is associated with increased early rejection & transplant atherosclerosis. Circulation 1992;86:I-628.
- 12: Fyfe AI, Baldwin GC, Demer LL: Cytomegalovirus infection of human endothelium increases binding of cardiac transplant recipient mononuclear cells. Circulation 1992;86:I-158.
- 13: Fyfe AI, Brownfield ED, Kobashigawa JA, Stevenson LW: Blood group B endothelia & serum induce high affinity binding of cardiac transplant recipient monocytes. Circulation 1992;86:I-36.
- 14: Fyfe AI, Berliner JA, Navab M, Demer LL, Stevenson LW: Monocytes of cardiac transplant recipients bind specific donor endothelium using HLA I/II and Mac-1/ICAM-1. Circulation 1992;86:I-83.
- 15: Mojibi N, Fyfe AI, Kobashigawa JA, Demer LL, Drinkwater DC, Laks H, Stevenson LW: Antibodies to vascular smooth muscle and endothelium after cardiac transplantation. Clin Res 1993;41:67A.
- 16: Fyfe AI, Navab M, Demer LL, Stevenson LW: Allograft specific adhesion of cardiac transplant recipient monocytes enhances trans-endothelial migration. J Am Coll Cardiol 1993;21:431A.
- 17: Fyfe AI, Berliner JA, Demer LL, Stevenson LW: Antibodies to T cell receptor (CD3) initiate mononuclear cell binding to arterial endothelium. J Am Coll Cardiol 1993;21:37A.

- 18: Fyfe AI, Mojibi N, Kobashigawa JA, Demer LL, Stevenson LW: Antibodies to vascular smooth muscle and endothelium after cardiac transplantation. *J Am Coll Cardiol*;1993;21: 334A.
- 19: Fyfe AI, Navab M, Demer LL, Stevenson LW: Heart transplant recipient mixed lymphocyte reaction induces sub-maximal class II HLA on donor endothelium. *J Am Coll Cardiol*;1993: 39A.
- 20: Fyfe AI, Demer LL, Drinkwater DC, Laks H, Stevenson LW: Antibodies to the T cell receptor initiate LFA-1/Mac-1 dependent mononuclear cell adhesion to arterial endothelium. *J Heart Lung Transplant* 1993;12:S72.
21. Burns RJ, Daly PA, Fyfe AI, Cardella CJ, Wright LM: Evaluation of Human Cardiac Transplant Allograft Vasculopathy by Tc-99m Teboroxime Washout. *Journal of Nuclear Medicine* 1993;
- 22: Fyfe AI, Harper CM, Berliner JA, Stevenson LW: Anti-thymocyte globulin and OKT3 have opposite effects on adhesion of cardiac transplant recipient mononuclear cells to arterial endothelium. *Can J Cardiol* 1993;9:72E.
- 23: Fyfe AI, Ardehali A, Qiao J-H, Drinkwater DC, Laks H, Stevenson LW, Lusic AJ: Expression of a peri-operatively transfected reporter gene in a functioning mouse cardiac isograft. *Can J Cardiol* 1993;9:74E
- 24: Fyfe AI, Harper CM: Anti-thymocyte globulin and OKT3 have opposite effects on adhesion of cardiac transplant recipient mononuclear cells to arterial endothelium. *Circulation* 1993;1-41.
- 25: Ardehali A, Fyfe AI, Laks H, Drinkwater DC, Qiao, J-H, Lusic AJ: Transfection of transplanted mouse hearts by intracoronary infusion of a reporter plasmid. *Circulation* 1993;88:1-419
- 26: Fyfe AI, Harper CM, Stevenson LW, Berliner JA: Donor specific lymphocytes induce non-specific monocytes to adhere to arterial endothelium via p-selectin. *Circulation* 1993;88:1-78
- 27: Fyfe AI, Elsayegh A, Kobashigawa JA, Lusic AJ: Anti-chlamydia antibodies after cardiac transplantation are associated with transplant coronary disease. *Circulation* 1993;88:1-481.
- 28: Fyfe AI, Ardehali A, Laks H, Lusic AJ: Intracoronary liposome mediated gene transfer of human HLA-B7 into mouse heart transplants at the time of harvest is associated with acute cellular rejection. *J Cellular Biochem* 1994: 18A:301.
- 29: Ardehali A, Laks H, Fyfe AI, Drinkwater DC, Qiao J-H, Lusic AJ: Can donor hearts be genetically modified prior to transplantation. *J Thoracic Cardiovasc Surg* 1994:
- 30: Fyfe AI, Qiao J-H, Lusic AJ. Immunodeficient mice develop typical atherosclerosis when fed an atherogenic diet. *Circulation* 1994;90:1-188.
- 31: Fyfe AI, Kwong SL, Harper CM: Psoralen/UV photochemotherapy inhibits human mononuclear-endothelial adhesion and mixed lymphocyte reactions. *Circulation* 1994;90:1-361.
- 32: Fyfe AI, Qiao JH, Lusic AJ: The immune system is not essential for the development of aortic atherosclerotic plaques in mice fed an atherogenic diet. *Atherosclerosis* 1994;109:8
- 33: Fyfe AI, Castellani LW, Rotter JI, Lusic AJ: Serum amyloid A levels are associated with coronary artery disease: the Cedars-Sinai family study. *Atherosclerosis* 1994;109:18.
34. Fyfe AI, Hedrick CC: Genetic modification of allograft endothelium using an interleukin-10 adenovirus inhibits recipient monocyte adhesion. *J Heart Lung Transplant* 1995;14:S54
35. Fyfe AI, Harper CM, Berliner JA. P-selectin Activation on Endothelial Cells by Allogeneic Lymphocytes by Interactions Between the Co-stimulatory Molecule B7-2 and Class I HLA. *Circulation* 1995;92:1-498

36. Fyfe AI, Harper CM. HMG-CoA Reductase Inhibitors Inhibit Activated Monocyte/Macrophage Surface Expression of Class I and II HLA Molecules. *Circulation* 1995;92:1-498
37. Fyfe AI, Hedrick CC, Harper CM, Fogelman AM, Berliner JA. An Interleukin-10 Recombinant Adenovirus Inhibits P-selectin Mediated Monocyte Adhesion to Human Aortic Endothelium. *Circulation* 1995;92:1-M
38. Fyfe AI, Hedrick CC, Watson AD, Fogelman AM, Berliner JA, Lusis AJ. Adenovirus Mediated Gene Transfer of bcl-2 To Endothelium Inhibits Monocyte Adhesion in Response to Oxidized Lipids. *Circulation* 1995;92:1-102.
39. Hedrick CC, Fyfe AI. Apolipoprotein A-II Transgenic Mice Display Enhanced Endotoxin Sensitivity. Joint Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Salt Lake City, UTAH 1996.
40. Fyfe AI, Hedrick CC. Serum Paraoxonase Inhibits the Biologic Activity of Bacterial Lipopolysaccharide/Lipid A. Joint Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Salt Lake City, UTAH 1996.
41. Oslund LJ, Fyfe AI. The Ability of Oxidized Lipoproteins to Modulate the Immune Responses is Dependent on its Physical State. Joint Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Salt Lake City, UTAH 1996.
42. Hedrick CC, Harper CM, Fyfe AI. Glycated HDL have altered function in vitro. *Diabetes* 1997;46(Suppl 1) 46A.
43. Fyfe AI, C57BL/6Ks as a mouse model of type II diabetes and atherosclerosis. International Symposium on Atherosclerosis Lyon, France 1997
44. Fyfe AI, Biologic Activity of Glycoxidatively Modified LDL and Phospholipids. International Symposium on Atherosclerosis Lyon, France 1997
45. Fyfe AI, Harper CM, Hedrick CC. C57BL/6Ks as a mouse model of type 2 diabetes and atherosclerosis. *Circulation* 1997;96:1-175.
46. Harper CM and Fyfe AI. HMG-CoA reductase inhibitors block multiple events in atherogenesis. *Circulation* 1997;96:1-177
47. Niwa K, Perloff JK, Miner P and Fyfe AI. Hypcholesterolemia in adults with cyanotic congenital heart disease. *Circulation* 1997;96:1-98
48. Oslund L, Hagenbaugh A, Tyner T, Berliner JA, Hedrick CC, Fyfe AI. Interleukin-10 inhibition of atherogenic events in vitro and in vivo. *Circulation* 1997;96:1-490
49. Fyfe AI, Perloff JK, Niwa K, Miner PD, Child JS. Cyanotic Congenital Heart Disease - an Atheroma-Free Model. *Circulation* 2000;98:11-767
50. Patenaude AF, Fyfe AI, Friede J. Inverse Relationship Between Simultaneously Measured Coronary Calcification and Bone Density in 12,000 Patients: Relationship to HDL Cholesterol. *JACC* 2002;39:381A
51. Fyfe AI, Rosenthal JE, Floyd BF, Brown D, Underwood RH. LDL Lipoprotein and Triglyceride Clearance by the Lung is Markedly Reduced in Congestive Heart Failure. *JACC* 2002;39:255A
52. Fyfe AI, Rosenthal JE, Floyd BF, Brown D, Underwood RH. Lipoprotein Remodeling Between HDL2 and Large VLDL Within the Coronary Circulation. *Circulation* 2002;100:11-253